07:00 , May 24, 2010 |  BioCentury  |  Finance

Normalizing oxygen

Investors are hoping to get the lead candidate for NormOxys Inc. through Phase IIa trials in two indications with $17.5 million from a series B1 round, Jerry Karabelas of Care Capital told Ebb & Flow....
08:00 , Jan 25, 2010 |  BioCentury  |  Finance

SVLS closes V fund

While the pace of venture fundraising suggests some VCs are having trouble raising new funds, SV Life Sciences has closed its fifth fund on target at $400 million, with the prospects of surpassing $500 million....
08:00 , Dec 21, 2009 |  BioCentury  |  Product Development

Valuing Array's Sensitive Side

Array BioPharma Inc. 's glucokinase activators are not the most advanced molecules in the class, but the biotech says they may have a competitive advantage in terms of safety due to their glucose sensitivity. Amgen...
08:00 , Nov 10, 2008 |  BioCentury  |  Finance

Biotech exits

Biotech exits...
07:00 , Aug 18, 2008 |  BioCentury  |  Finance

Ebb & Flow

Investors reached new heights of optimism after a special committee of three independent...
08:00 , Dec 17, 2007 |  BioCentury  |  Finance

Ebb & Flow

Dashing the hopes of buysiders,...
07:00 , Sep 3, 2007 |  BioCentury  |  Strategy

Innovation & leadership

Over the past two years, Back to School has been exploring the relationship between innovation and the economic returns from drug development and the creation of patient value. These discussions have argued that as pricing...
07:00 , Aug 27, 2007 |  BioCentury  |  Strategy

Targeting DPP-4

Targeting DPP-4...
07:00 , Jul 23, 2007 |  BC Week In Review  |  Company News

Alantos, Amgen deal

AMGN completed its previously announced acquisition of Alantos for $300 million in cash (see BioCentury, June 11). Alantos Pharmaceuticals Holding Inc. , Cambridge, Mass.   Amgen Inc. (AMGN), Thousand Oaks, Calif.   Business: Endocrine, Autoimmune...
07:00 , Jun 11, 2007 |  BioCentury  |  Finance

Ebb & Flow

The Street had a mixed reaction to the pair of private companies that...